Biofourmis Funding: $465M Raised, Series D (2022)

Biofourmis funding overview

Biofourmis is based in Singapore, Singapore. Biofourmis has raised $465M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in August 2022. The round record for Biofourmis runs through 2022; nothing later has been disclosed. Investors on record include General Atlantic, SoftBank Vision Fund, Sequoia Capital, MassMutual Ventures, Aviva plc, Mayo Clinic Ventures and 1 others. 7 distinct backers are named across the disclosed rounds.

Biofourmis at a glance

Total raised: $465M
Latest round: Series D
Latest round date: August 2022
Headquarters: Singapore, Singapore
Notable investors: General Atlantic, SoftBank Vision Fund, Sequoia Capital, MassMutual Ventures, Aviva plc, Mayo Clinic Ventures, CVS Health

Frequently asked about Biofourmis funding

How much has Biofourmis raised?: Biofourmis has raised $465M in total disclosed funding across the rounds on record.
Who has invested in Biofourmis?: General Atlantic, SoftBank Vision Fund, Sequoia Capital, MassMutual Ventures, Aviva plc, Mayo Clinic Ventures are named among the investors backing Biofourmis.
What was the latest Biofourmis funding round?: The most recent disclosed round is a Series D, announced in August 2022.
Where is Biofourmis based?: Biofourmis is based in Singapore, Singapore.
When did Biofourmis last raise?: The last disclosed Biofourmis round closed in August 2022 at Series D.

Every Biofourmis figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Singapore at a similar stage.

Biofourmis Funding: $465M Raised, Series D (2022)

Biofourmis funding overview

Biofourmis at a glance

Frequently asked about Biofourmis funding

Companies related to Biofourmis (36)

Browse related funding lists (8)